Access HBV Assays - European Union (EU) Clinical Trial Protocol -
Evaluation of the Beckman Coulter Access Hepatitis B Virus (HBV) Serological Marker Assays As an Aid in the Diagnosis of HBV Infection: EU Clinical Trial Protocol
Beckman Coulter, Inc.
21,210 participants
Oct 15, 2019
OBSERVATIONAL
Conditions
Summary
The objective of this protocol is the collection and testing of clinical samples to determine the clinical performance of the Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer. The study will involve a multicenter, prospective and retrospective collection of samples, and testing of samples with the investigational Hepatitis B Virus assays as required per the European Union Common Technical Specification. All samples collected will be anonymized or pseudo-anonymised, leftover, remnant samples. Pseudo-anonymised collection of samples will require documented patient consent (oral or written).
Eligibility
Inclusion Criteria14
- Subject aged ≥ 18 years,
- Subject who has provided consent (oral or written) or sample collected under waiver
- With sufficient volume to perform clinical trial testing
- And belonging to one of the following enrollment groups:
- Unselected blood donors
- Hospitalized patients
- Presumed HBsAg positive patients by Confirmatory testing of a CE-marked assay
- Patients having recovered from natural HBV infection, presumed Anti-HBs positive (i.e. Anti-HBs and Anti-HBc Total positive by CE-marked assays)
- Patients having received HBV vaccination, presumed Anti-HBs positive (confirmed by testing at the time of enrollment, i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).
- Presumed Anti-HBc Total positive patients by a CE-marked assay
- Presumed Anti-HBc IgM positive patients by a CE-marked assay with acute/recent HBV infection 8
- Presumed HBeAg positive patients by a CE-marked assay
- Presumed Anti-HBe positive patients by a CE-marked assay
- Patients with chronic HBV infection
Exclusion Criteria1
- Samples from subjects already included in the study\* (\* Patient can be included only once per HBV marker study, but can potentially be enrolled for several separate HBV marker studies.)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04904835